Q-omics provides the consensus-scored ARID4A profile across patient tissues and cancer cell-line models. ARID4A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARID4A is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, ARID4A RNA expression shows 21,314 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUSC, and ACC as cancer lineages where ARID4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARID4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARID4A survival associations across molecular data types. ARID4A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARID4A RNA expression–survival associations across cancer types. High ARID4A expression shows unfavorable associations in ACC and UVM, but favorable associations in KIRC, HNSC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARID4A RNA expression.
This table summarizes ARID4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARID4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARID4A shows lower tumor expression in LUSC, LUAD, KICH, UCEC, THCA and BRCA. The LUSC box plot shows higher ARID4A RNA expression in normal versus tumor tissue (log2 FC = −0.851, t-test p < 0.001).
This table shows molecular features associated with ARID4A in patient tissues and cancer cell lines. In patient samples, ARID4A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARID4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
